Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia

Abstract

Telithromycin 800 mg administered once a day for 5 or 7 days was as effective and safe as clarithromycin 500 mg administered twice a day for 10 days in treating patients with CAP caused by common respiratory pathogens, including macrolide-resistant isolates, and pneumococcal bacteraemia.

Influences on the start, selection and duration of treatment with antibiotics in long-term care facilities

“…We selected a cut-off of more than 7 days of treatment based on evidence that most bacterial infections can be treated with a duration of 7 days or less of antibiotics. 6,[34][35][36][37][38] We considered consecutive prescriptions for the same antibiotic to be part of the same treatment course if the drug was prescribed by the same physician, to the same patient and there was no more than 3 days between prescriptions.…”

Containing Costs and Containing Bugs: Are They Mutually Exclusive?

“…[41][42][43] Though these studies show that the efficacy of short-course regimens is comparable to the efficacy of longer courses, they tend to only include patients with mildto-moderate disease and/or who were primarily treated on an outpatient basis. A study by Dunbar et al, however, compared the 750 mg dose of levofloxacin for 5 days with 500 mg for 10 days for patients with mild-to-severe CAP.…”

Cethromycin versus Clarithromycin for Community-Acquired Pneumonia: Comparative Efficacy and Safety Outcomes from Two Double-Blinded, Randomized, Parallel-Group, Multicenter, Multinational Noninferiority Studies

“…Clinical cure rates for cethromycin were consistent between the two trials; however, the clinical cure rates for clarithromycin in the CL06-001 trial were extraordinarily high. Interestingly, a review of published clarithromycin clinical trial results shows that cure rates of this magnitude have never been seen before with clarithromycin in a similar patient population (23,33). Examination of the data, including subgroup analysis, geographical differences, seasonality, or disease severity, has been unsuccessful in explaining this result (1).…”